Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Ustekinumab & Psoriasis (Psoriasis vulgaris, Nummular psoriasis, Plaque psoriasis)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Currently, data support the use of ustekinumab in the treatment of psoriatic arthritis following the failure of Cyclooxygenase inhibitors / Nonsteroidal anti-inflammatory drugs (NSAIDs) and conventional disease-modifying antirheumatic diseases as an alternative to or following the failure of an Tumor Necrosis Factor alfa (TNF-alfa) antibodies / Tumor Necrosis Factor alfa (TNF-alfa) inhibitors
Robert et al. 2018 Immunotherapy 10: 361-372
…

A review of ustekinumab in the treatment of psoriatic arthritis
Robert et al. 2018 Immunotherapy 10: 361-372
Review
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Reich et al. 2021 The Lancet 397: 487-498
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Gordon et al. 2018 the lancet 392: 650-661

7/2/2026